Acquired flucytosine resistance during combination therapy with caspofungin and flucytosine for Candida glabrata cystitis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 1, 2016, Pages 662-665

  Charlier, Caroline ^a   El Sissy, Carine ^a   Bachelier Bassi, Sophie ^b   Scemla, Anne ^a   Quesne, Gilles ^a   Sitterlé, Emilie ^a   Legendre, Christophe ^a   Lortholary, Olivier ^a   Bougnoux, Marie Elisabeth ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPOFUNGIN; FLUCYTOSINE; ANTIFUNGAL AGENT; ECHINOCANDIN; FUNGAL PROTEIN; LIPOPEPTIDE; NUCLEOBASE TRANSPORTER; STOP CODON;

AGED; ANTIFUNGAL RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; CANDIDURIA; CASE REPORT; CYSTITIS; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FUNGAL GENE; FUR1 GENE; HUMAN; MALE; MEDICAL HISTORY; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; STOP CODON; URINE CULTURE; BLADDER; CANDIDA GLABRATA; CANDIDIASIS; COMBINATION DRUG THERAPY; DRUG EFFECTS; GENE EXPRESSION; GENETICS; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGY; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; TREATMENT FAILURE;

AGED; ANTIFUNGAL AGENTS; BASE SEQUENCE; CANDIDA GLABRATA; CANDIDIASIS; CODON, NONSENSE; CYSTITIS; DRUG RESISTANCE, FUNGAL; DRUG THERAPY, COMBINATION; ECHINOCANDINS; FEMALE; FLUCYTOSINE; FUNGAL PROTEINS; GENE EXPRESSION; HUMANS; LIPOPEPTIDES; MALE; MOLECULAR SEQUENCE DATA; NUCLEOBASE TRANSPORT PROTEINS; TREATMENT FAILURE; URINARY BLADDER;

EID: 84957916943     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02265-15     Document Type: Article

References (14)

1. Fisher JF, Sobel JD, Kauffman CA, Newman CA. 2011. Candida urinary tract infections - treatment. Clin Infect Dis 52(Suppl 6):S457-S466. http://dx.doi.org/10.1093/cid/cir112.
2. Denning DW. 2003. Echinocandin antifungal drugs. Lancet 362:1142-1151. http://dx.doi.org/10.1016/S0140-6736(03)14472-8.
3. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, Bille J, Castagnola E, Cuenca-Estrella M, Donnelly JP, Groll AH, Herbrecht R, Hope WW, Jensen HE, Lass-Florl C, Petrikkos G, Richardson MD, Roilides E, Verweij PE, Viscoli C, Ullmann AJ. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 18(Suppl 7):S19-S37.
4. Sobel JD, Bradshaw SK, Lipka CJ, Kartsonis NA. 2007. Caspofungin in the treatment of symptomatic candiduria. Clin Infect Dis 44:e46-e49. http://dx.doi.org/10.1086/510432.
5. Edlind TD, Katiyar SK. 2010. Mutational analysis of flucytosine resistance in Candida glabrata. Antimicrob Agents Chemother 54:4733-4738. http://dx.doi.org/10.1128/AAC.00605-10.
6. Inglis DO, Arnaud MB, Binkley J, Shah P, Skrzypek MS, Wymore F, Binkley G, Miyasato SR, Simison M, Sherlock G. 2012. The Candida genome database incorporates multiple Candida species: multispecies search and analysis tools with curated gene and protein information for Candida albicans and Candida glabrata. Nucleic Acids Res 40:D667-D674. http://dx.doi.org/10.1093/nar/gkr945.
7. Vaughn JN, Bennetzen JL. 2014. Natural insertions in rice commonly form tandem duplications indicative of patch-mediated double-strand break induction and repair. Proc Natl Acad Sci U S A 111:6684-6689. http://dx.doi.org/10.1073/pnas.1321854111.
8. Dodgson AR, Pujol C, Denning DW, Soll DR, Fox AJ. 2003. Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. J Clin Microbiol 41:5709-5717. http://dx.doi.org/10.1128/JCM.41.12.5709-5717.2003.
9. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, Herbrecht R, Ruiz-Palacios G, Young JA, Baddley JW, Strohmaier KM, Tucker KA, Taylor AF, Kartsonis NA. 2009. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 48:1676-1684. http://dx.doi.org/10.1086/598933.
10. Howard SJ, Livermore J, Sharp A, Goodwin J, Gregson L, Alastruey-Izquierdo A, Perlin DS, Warn PA, Hope WW. 2011. Pharmacodynamics of echinocandins against Candida glabrata: requirement for dosage escalation to achieve maximal antifungal activity in neutropenic hosts. Antimicrob Agents Chemother 55:4880-4887. http://dx.doi.org/10.1128/AAC.00621-11.
11. Paladino JA, Crass RE. 1982. Amphotericin B and flucytosine in the treatment of candidal cystitis. Clin Pharm 1:349-352.
12. Chapeland-Leclerc F, Hennequin C, Papon N, Noel T, Girard A, Socie G, Ribaud P, Lacroix C. 2010. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 54:1360-1362. http://dx.doi.org/10.1128/AAC.01138-09.
13. Logan RL, Goldberg MJ. 1972. C. albicans resistance to 5-fluorocytosine. Br Med J 3:531.
14. Hoeprich PD, Ingraham JL, Kleker E, Winship MJ. 1974. Development of resistance to 5-fluorocytosine in Candida parapsilosis during therapy. J Infect Dis 130:112-118. http://dx.doi.org/10.1093/infdis/130.2.112.